Corticosteroid-resistant immune-related adverse events: a systematic review.

"Competing interests: ED: None. TW: None. DK: Received consulting/advisor fees from AstraZeneca, Amgen, Sanofi, Merck Sharp & Drohne, MSD and support for attending meetings and/or travel from Amgen, Roche, Sanofi. AZ: Received consulting/advisor fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Hoffmann–La Roche, NBE Therapeutics, Secarna, ACM Pharma, and Hookipa, and maintains further non-commercial research agreements with Secarna, Roche, Vectorbiopharma, T3 Pharma and Bright Peak Therapeutics. HL: Received travel grants and consultant fees from BMS, Alector, and MSD; received research support from BMS, Novartis, GlycoEra and Palleon Pharmaceuticals. JN: Received consulting/advisor fees from AstraZeneca, Bristol-Myers Squibb, Roche/Genentech, Arcus Biosciences, NGM Pharmaceuticals, Bayer, Regeneron, Takeda, Pfizer, Elevation Oncology, AbbVie, Kaleido Biosciences, Daiichi Sankyo. JN: Received research support from AstraZeneca, Bristol-Myers Squibb, Roche/Genentech, Arcus Biosciences and Mirati. LC: Research funding from Bristol-Myers Squibb."

"Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors."